- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02599298
Sleep Study-Guided Multidisciplinary Therapy for Patients Presenting With Acute Coronary Syndrome (SGMT)
The aim of this randomized, open-label clinical trial is to determine the impact of Sleep Study-Guided Multidisciplinary Therapy (SGMT, i.e. continuous positive airway pressure and behavioral therapy) for obstructive sleep apnea (OSA) in the sub-acute phase of acute coronary syndrome on cardiovascular outcomes. We hypothesize that SGMT will result in a lower (1) plasma NT-pro BNP, ST2 levels and hs-CRP, (2) 10-year risk of cardiovascular mortality based on the European SCORE algorithm, and (3) cardiovascular event rate, when compared with Standard Therapy.
OSA is an emerging cardiac risk factor and prognostic marker. We have reported that OSA is a prevalent and independent predictor of adverse outcomes in patients with acute coronary syndrome. In this clinical trial, a continuation of my research and publication trajectory, 180 patients presenting with acute coronary syndrome will be randomly assigned to SGMT (n=90) or Standard Therapy (n=90) groups. Both groups will receive guideline-mandated treatment for acute coronary syndrome. Those assigned to SGMT will undergo a sleep study. Those found to have OSA will attend the SGMT clinic run by a multidisciplinary team. Advice on continuous positive airway pressure and behavioral therapy (weight loss, exercise, positional therapy, abstinence of alcohol and sleeping pills) will be given. The primary endpoint is plasma NT-pro BNP concentration at 6-month follow-up. The secondary endpoints are ST2, hs-CRP, 10-year risk of cardiovascular mortality based on the European SCORE algorithm which includes age, sex, smoking status, systolic blood pressure, and serum total cholesterol or total/HDL-cholesterol ratio. Adverse cardiovascular events at 3-year follow-up will be determined.
In our aging population with an increasing prevalence of obesity, OSA will potentially become an increasingly important contributor to cardiovascular disease. Leveraging the collective expertise of a team of cardiologists and sleep physicians, our work will benefit society by advancing our understanding of the cardiovascular benefits of screening for and treating OSA.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Acute coronary syndrome is a leading cause of mortality and morbidity globally. The Principal Investigator (PI) has been conducting research on sleep medicine and cardiovascular disease since 2007. Our early work has shown that obstructive sleep apnea (OSA) is prevalent in patients presenting with an acute coronary syndrome, and carries negative prognostic implications. This Clinician Scientist Award application is centered on the potential cardiovascular benefits of a Sleep Study-Guided Multidisciplinary Therapy (SGMT) that includes continuous positive airway pressure (CPAP) and behavioral therapy for patients presenting with an acute coronary syndrome, which could lead to a potential paradigm shift in patient management during the sub-acute phase of the syndrome. For this application, we have assembled a team of experts in cardiovascular medicine and sleep medicine. Using the leverage of the synergistic expertise of the assembled leaders and the knowledge generated in the early part of the program, we will embark on a therapeutic trial.
In this randomized trial, 180 patients presenting with an acute coronary syndrome will be recruited and randomized into SGMT versus standard therapy (without sleep study) groups. Both groups will be treated with a guideline-mandated therapy for acute coronary syndrome (including regular cardiology outpatient clinic visits after discharge). In those allocated to SGMT, an overnight sleep study using a level 3 portable diagnostic device will be carried out. Those with OSA (an estimated 75% according to the pilot data) will be treated with CPAP and behavioral therapy. Plasma N-terminal pro-brain natriuretic peptide (NT-proBNP), ST2, and hs-CRP levels will be measured before hospital discharge and at 6-month follow-up. The 10-year risk of cardiovascular mortality based on the European cardiovascular risk score (SCORE), which includes age, sex, smoking status, systolic blood pressure, and serum total cholesterol or total/high-density lipoprotein (HDL)-cholesterol ratio, will be determined at baseline and at 6-month follow-up.
Our specific aims are to compare the effects of SGMT and standard therapy on:
- Plasma levels of NT-proBNP (Primary endpoint), ST2 and hs-CRP. We hypothesize that SGMT will be associated with a lower plasma NT-proBNP, ST2 and hs-CRP levels than standard therapy at 6-month follow-up.
- Systematic COronary Risk Evaluation (SCORE). We hypothesize that SGMT will be associated with a lower SCORE than standard therapy at 6-month follow-up.
- Incidence of major adverse cardiac events (extended study). We hypothesize that SGMT will be associated with a lower incidence of major adverse cardiac events at 3-year follow-up (an application for additional funding will be made to accomplish this aim).
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Singapore, Singapore, 119228
- Chi-Hang Lee
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age > 21 years, admission with an acute coronary syndrome, competent informed consent, and the ability to follow all protocol procedures.
Exclusion Criteria:
- Known OSA being treated by CPAP, recommended coronary artery bypass surgery, concomitant moderate to severe structural valve disease, clinical instability (decompensated hypotension, heart failure, shock, refractory ventricular arrhythmias, acute conduction system disease, implanted defibrillator, or left ventricular ejection fraction ≤ 30%), limited life expectancy (< 1 year) due to a concomitant illness, prior or planned heart transplant or any other organ transplant, pregnancy or current nursing activity, or inability to give informed consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: SGMT arm
Treatment of OSA requires a multidisciplinary approach, involving a sleep physician and paramedical staff with expertise in the management of sleep disorders.
An initial medical assessment is needed to confirm the diagnosis of OSA, determine its severity and decide whether CPAP therapy is appropriate.
As part of this evaluation, an objective overnight sleep study will be performed.
This will be followed by an assessment, education, and counseling at the multidisciplinary therapy clinic.
|
Other Names:
|
No Intervention: Control arm
The patients will be treated according to the standard treatment for acute coronary syndrome in Singapore, which is largely in accordance with the recommendations of the American College of Cardiology and the American Heart Association.
Management includes, but is not limited to, antiplatelet and lipid-lowering therapy, early coronary revascularization, and cardiac rehabilitation, with the recommendation to follow the current practice and the most recent international guidelines.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Plasma concentration of NT-proBNP
Time Frame: 6-month
|
6-month
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
European cardiovascular risk SCORE
Time Frame: 6-month
|
6-month
|
Composite clinical endpoint of cardiovascular death, myocardial infarction (Q-wave and non-Q wave), stroke, unplanned revascularization, and hospitalization for heart failure
Time Frame: 12-month
|
12-month
|
Plasma concentration of ST2
Time Frame: 6-month
|
6-month
|
Plasma concentration of hs-CRP
Time Frame: 6-month
|
6-month
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Compliance to CPAP
Time Frame: 6-month
|
6-month
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Myocardial Ischemia
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Nervous System Diseases
- Respiratory Tract Diseases
- Apnea
- Respiration Disorders
- Sleep Disorders, Intrinsic
- Dyssomnias
- Sleep Wake Disorders
- Disease
- Sleep Apnea Syndromes
- Sleep Apnea, Obstructive
- Syndrome
- Acute Coronary Syndrome
Other Study ID Numbers
- NMRC CSA 2015
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obstructive Sleep Apnea
-
Mauro ManconiCompletedObstructive Sleep Apnea Syndrome | Sleep Apnea, Obstructive | Obstructive Sleep Apnea | OSA | Apnea, Obstructive | OSAHSwitzerland
-
LivaNovaRecruitingApnea | Obstructive Sleep Apnea | OSA | Apnea, Obstructive | Apnea+Hypopnea | Apnea, Obstructive Sleep | Hypopnea, SleepUnited States
-
University of California, Los AngelesRecruiting
-
Brigham and Women's HospitalCompletedObstructive Sleep Apnea (OSA)United States
-
State Budgetary Healthcare Institution, National...RecruitingObstructive Sleep Apnea | Obstructive Sleep Apnea-hypopnea | Obstructive Sleep Apnea-hypopnea SyndromeRussian Federation
-
The Hospital for Sick ChildrenCompleted
-
Cryosa, Inc.Active, not recruitingObstructive Sleep Apnea of AdultPanama, Paraguay
-
State Key Laboratory of Respiratory DiseaseCompletedObstructive Sleep Apnea of AdultChina
-
Somnics, Inc.UnknownObstructive Sleep Apnea of AdultTaiwan
-
ResMedCompletedObstructive Sleep Apnea (OSA)United States, Australia
Clinical Trials on Continuous Positive Airway Therapy
-
University Hospital OlomoucCompleted
-
Nagoya UniversityUnknown
-
University Health Network, TorontoSunnybrook Health Sciences CentreRecruitingSpinal Cord Injuries | Spine DiseaseCanada
-
University Health Network, TorontoThe Craig H. Neilsen FoundationRecruitingSleep Apnea | Spinal Cord InjuriesCanada
-
University of PennsylvaniaNational Institute on Aging (NIA)Active, not recruitingSleep Apnea, Obstructive | Mild Cognitive ImpairmentUnited States
-
Angeles Sanchez ArmengolBeca de Excelencia de la CICE de la Junta de Andalucia y programa Operativo...Completed
-
Women's College HospitalUniversity Health Network, TorontoWithdrawnObstructive Sleep Apnea | FibromyalgiaCanada
-
University Hospital, GrenobleResMed; Société francophone de pneumologie de langue francaiseCompletedType 1 Diabetes | Sleep Apnea SyndromeFrance
-
University Hospital, MontpellierCompletedCoronary Artery Disease | Sleep Apnea SyndromeFrance
-
Sanjay R PatelBeth Israel Deaconess Medical Center; National Institutes of Health (NIH); Brigham...CompletedSleep Apnea, Obstructive | Diabetes MellitusUnited States